Evidence map›Paper›PMID 36899091›Full record

ArticleProstate cancer and prostatic diseases2023

Correction: Overall survival and adverse events after treatment with darolutamide vs. apalutamide vs. enzalutamide for high-risk non-metastatic castration-resistant prostate cancer: a systematic review and network meta-analysis.

Mike Wenzel, Luigi Nocera, Claudia Collà Ruvolo, Christoph Würnschimmel, Zhe Tian, Shahrokh F Shariat, Fred Saad, Derya Tilki, Markus Graefen, Luis A Kluth and 5 more

Open access · hybridAbstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Prostate cancer and prostatic diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 96% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

15 authors at 5 institutions in 8 countries.

Mike Wenzel *Department of Urology, Goethe University Hospital Frankfurt, Frankfurt am Main, Germany. Mike.Wenzel@kgu.de.ORCID http://orcid.org/0000-0002-4338-0889
Luigi Nocera *Division of Urology, Cancer Prognostics and Health Outcomes Unit, University of Montréal Health Center, Montréal, QC, Canada.ORCID http://orcid.org/0000-0003-3354-8139
Claudia Collà RuvoloDivision of Urology, Cancer Prognostics and Health Outcomes Unit, University of Montréal Health Center, Montréal, QC, Canada.ORCID http://orcid.org/0000-0001-8110-7341
Christoph WürnschimmelDivision of Urology, Cancer Prognostics and Health Outcomes Unit, University of Montréal Health Center, Montréal, QC, Canada.ORCID http://orcid.org/0000-0001-7891-4791
Zhe TianDivision of Urology, Cancer Prognostics and Health Outcomes Unit, University of Montréal Health Center, Montréal, QC, Canada.
Shahrokh F ShariatDepartment of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.ORCID http://orcid.org/0000-0003-1426-9273
Fred SaadDivision of Urology, Cancer Prognostics and Health Outcomes Unit, University of Montréal Health Center, Montréal, QC, Canada.
Derya TilkiMartini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany.ORCID http://orcid.org/0000-0001-7033-1380
Markus GraefenMartini-Klinik Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany.
Luis A KluthDepartment of Urology, Goethe University Hospital Frankfurt, Frankfurt am Main, Germany.
Alberto BrigantiDepartment of Urology and Division of Experimental Oncology, URI, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Philipp MandelDepartment of Urology, Goethe University Hospital Frankfurt, Frankfurt am Main, Germany.
Francesco MontorsiDepartment of Urology and Division of Experimental Oncology, URI, Urological Research Institute, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Felix K H ChunDepartment of Urology, Goethe University Hospital Frankfurt, Frankfurt am Main, Germany.
Pierre I KarakiewiczDivision of Urology, Cancer Prognostics and Health Outcomes Unit, University of Montréal Health Center, Montréal, QC, Canada.
Goethe University Frankfurt · DEUniversité de Montréal · CAIstituti di Ricovero e Cura a Carattere Scientifico · ITUniversität Hamburg · DEUniversity of Jordan · JO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID36899091
PMCPMC10638077
OpenAlexW4323842692

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.